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Abstract
The switch between latent and lytic Epstein-Barr virus (EBV) infection is mediated by the viral immediate-early (IE) protein,
BZLF1 (Z). Z, a homologue of c-jun that binds to AP1-like motifs (ZREs), induces expression of the BRLF1 (R) and BRRF1 (Na)
viral proteins, which cooperatively activate transcription of the Z promoter and thereby establish a positive autoregulatory
loop. A unique feature of Z is its ability to preferentially bind to, and activate, the methylated form of the BRLF1 promoter
(Rp). To date, however, Rp is the only EBV promoter known to be regulated in this unusual manner. We now demonstrate
that the promoter driving transcription of the early BRRF1 gene (Nap) has two CpG-containing ZREs (ACGCTCA and
TCGCCCG) that are only bound by Z in the methylated state. Both Nap ZREs are highly methylated in cells with latent EBV
infection. Z efficiently activates the methylated, but not unmethylated, form of Nap in reporter gene assays, and both ZREs
are required. Z serine residue 186, which was previously shown to be required for Z binding to methylated ZREs in Rp, but
not for Z binding to the AP1 site, is required for Z binding to methylated Nap ZREs. The Z(S186A) mutant cannot activate
methylated Nap in reporter gene assays and does not induce Na expression in cells with latent EBV infection. Molecular
modeling studies of Z bound to the methylated Nap ZREs help to explain why methylation is required for Z binding, and the
role of the Z Ser186 residue. Methylation-dependent Z binding to critical viral promoters may enhance lytic reactivation in
latently infected cells, where the viral genome is heavily methylated. Conversely, since the incoming viral genome is initially
unmethylated, methylation-dependent Z activation may also help the virus to establish latency following infection.
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Introduction
Epstein-Barr virus (EBV) is a human gammaherpesvirus
associated with B-cell lymphomas, nasopharyngeal carcinoma
(NPC) and gastric cancer [1,2]. EBV primarily infects two cell
types, epithelial cells and B cells [1,3]. As is the case for all
herpesviruses, EBV can infect cells in either latent, or lytic, forms.
Lytic replication, which is required for horizontal spread of the
virus from cell to cell, and from host to host, occurs in epithelial
cells and following differentiation of B cells into plasma cells [1,4–
7]. Lytic replication is mediated by the virally encoded DNA
polymerase using the oriLyt replication origin, and results in the
release of infectious viral particles [8]. In contrast, during latent
viral infection (which normally occurs in memory B cells), only a
subset of viral genes is expressed, the genome is replicated once per
cell cycle using the cellular DNA polymerase and the oriP
replication origin, and progeny virus is not released. Latent EBV
infection allows the virus to persist for the life of the host and avoid
detection by the immune system [1,4]. Thus, both the latent and
lytic forms of EBV infection are essential for viral pathogenesis.
The switch from latent to lytic infection is mediated by the
immediate-early (IE) proteins BZLF1 (Z) and BRLF1 (R) [4,6,9–
11]. Z and R are transcription factors which activate one another’s
promoters, as well as their own promoters [8]. In combination, Z
and R induce expression of all early lytic viral proteins, allowing
the virus to replicate. Z is a bZip protein homologous to c-jun and
c-fos that binds to the consensus AP1 motif as well as atypical AP1-
like motifs known as Z-responsive elements (ZREs) [12–15]. R
activates some early promoters through a direct binding
mechanism, but activates the BZLF1 promoter indirectly through
effects on cellular transcription factors (c-jun and ATF-2) binding
to a CRE motif [16,17]. An early viral protein, Na (encoded by the
BRRF1 gene located on the opposite strand of the first R intron),
induces c-jun phosphorylation and cooperates with R to enhance
BZLF1 transcription [18,19]. The Na homologues in KSHV
(ORF49) and MHV-68 (ORF49) likewise collaborate with their R
homologues (KSHV ORF50 and MHV-68 Rta) to activate lytic
viral promoters [20,21].
The EBV genome is not methylated in virions. However, in cells
with long-term latent infection, the majority of the EBV genome
becomes highly methylated [22–24]. DNA methylation, which
plays a critical role in modulating the expression of both cellular
and viral genes, induces transcriptional repression by multiple
different mechanisms, including prevention of transcription factor
binding to DNA and the recruitment of HDAC complexes [25–
33]. Surprisingly, while DNA methylation of the EBV IE BRLF1
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promoter (Rp) inhibits its activation by cellular transcription
factors, it enhances the ability of Z to activate the Rp [34]. This
unusual effect of Rp methylation on Z activation is due to the
enhanced ability of Z to bind to the methylated, versus
unmethylated, forms of two atypical CpG-containing Rp ZRE
sites (Rp ZRE2 and Rp ZRE3), and requires serine residue 186 in
the basic DNA domain of Z [22,34]. The Rp also has one CpG-
free ZRE, and can be activated by Z in the unmethylated form,
albeit it less efficiently [34]. Although the crystal structure of Z
bound to the consensus AP1 site has been previously published
[35], the structure of Z bound to methylated site has not been
published.
Z is the only transcription factor known to preferentially activate
the methylated form of a target promoter. To date, however, the
Rp is the only EBV promoter shown to have CpG-containing
ZREs. A variety of studies have suggested that Rp activation is the
essential first step required for Z disruption of viral latency, and
that both Z and R expression are required for induction of most
early lytic genes in the context of the intact viral genome [36,37].
The apparently unique effect of methylation on Z binding to the
Rp, but not other lytic viral promoters, may ensure that at the
earliest stages of viral reactivation limiting amounts of Z are
initially bound to the Rp rather than other lytic viral promoters.
In this paper, we demonstrate that the Na early lytic viral
promoter (Nap) has two CpG-containing ZREs that can only be
bound by Z in the methylated form. Furthermore, we show that
Nap methylation is required for efficient Z activation of the Nap.
We also demonstrate that the CpG motifs in the Nap ZREs are
usually methylated on the EBV genome during latent infection,
and that a Z mutant, Z(S186A), which cannot bind to the
methylated Nap ZREs in vitro is unable to activate Na expression in
latently infected cells. Our molecular modeling of Z bound to the
newly discovered methylated ZREs in the Nap, versus the
consensus AP1 site, helps to explain why methylation is required
for Z binding to some ZREs, and the role that the Z Ser186
residue plays in this binding. The apparently unique ability of Z to
activate the methylated forms of the R and Na promoters, but not
other lytic EBV promoters, may be a mechanism by which the
virus ensures that R and Na are the first genes activated during Z-
mediated reactivation in latently infected cells. Conversely, the
inability of Z to activate R and Na transcription efficiently from




293 cells infected with the Z-KO virus (293 Z-KO) were a gift
from Henri-Jacques Delecluse and have been described previously
[38]. 293 Z-KO were maintained in Dulbecco’s modified Eagle
medium (DMEM) containing 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and hygromycin B (100 mg/mL; Roche).
DG75, an EBV-negative B-cell lymphoma line, Raji, an EBV-
positive Burkitt lymphoma cell line, HONE-1 (a gift from Ronald
Glaser), an EBV-negative human nasopharyngeal carcinoma (NPC)
cell line, and SNU-719, a naturally derived EBV-infected gastric
carcinoma cell line [39], were maintained in RPMI 1640 medium
with 10% FBS and 1% penicillin-streptomycin. HeLa, a cervical
adenocarcinoma line, were maintained in DMEM with 10% FBS
and penicillin-streptomycin. HaCaT, a human keratinocyte cell line
[40], were maintained in F media with 10% FBS and penicillin-
streptomycin. HONE-1/EBV (a gift from Lawrence Young) is a
human NPC cell line that stably maintains the EBV (Akata strain)
genome under G418 selection in a latent form [41]. HONE-1/EBV
cells were maintained in RPMI medium 1640 with 10% FBS,
penicillin-streptomycin and G418 (400 mg/mL; Sigma).
Plasmids
Plasmid DNA was purified through columns as described by the
manufacturer (QIAGEN). Nap-LUC contains the Nap sequences
from +76 to 2209 (relative to the BRRF1 transcription start site)
inserted upstream of the luciferase gene in the pGL3-basic vector
(Promega). Mutations to the Nap-LUC construct were created
using the QuikChange site-directed mutagenesis kit (Stratagene).
Rp-LUC contains the Rp sequences from +37 to 21069 (relative
to the BRLF1 transcription start site) inserted upstream of the
luciferase gene in the pGL3-basic vector (Promega). BHLF1p-
LUC was constructed by PCR amplifying the divergent BHLF1
and BHRF1 promoter sequences (from 52781 to 53797) within the
oriLyt region from EBV B95.8 genomic DNA and inserting it in
the pBSLUCCAT construct; this plasmid contains the firefly
luciferase gene under the transcriptional control of the BHLF1
promoter and CAT gene under the control of the BHRF1
promoter. The Z expression vector (pSG5-Z) contains genomic Z
downstream of the SV40 promoter (a gift from S. Diane Hayward)
in the pSG5 vector (Stratagene). The Z cDNA (a gift from Paul
Farrell) was cloned into the pSG5 vector to create pSG5-ZcDNA,
which was used to in vitro translate the Z protein. Z(S186A) and
Z(C189S) mutations in the pSG5-ZcDNA vector were constructed
using the QuikChange site-directed mutagenesis kit (Stratagene) to
allow in vitro translation of the mutant proteins. The R expression
plasmid contains genomic R sequences downstream of the SV40
promoter in the pSG5 vector (a gift from S. Diane Hayward).
DNA transfection
Transfections of 293 Z-KO and HONE-1 cells were performed
by use of Lipofectamine 2000 (Invitrogen). Cells (86105) were
seeded the day prior to transfection in 2 mL of medium in a six-
well plate. Transfections were performed according to the
manufacturer’s instructions, except that the reagent:DNA ratio
was 3 mL:1.5 mg. Transfections of HeLa and HaCaT cells for
reporter assays were performed by use of Fugene 6 (Roche)
according to the manufacturer’s instructions. DG75 cells were
electroporated using 10 mg DNA with the Bio-Rad Gene Pulser
Xcell device, using 250 V, 975 mF, ‘ V, 4 mm cuvettes.
Author Summary
In cells with long-term latent Epstein-Barr virus (EBV)
infection, the majority of the EBV genome becomes highly
methylated. Methylation of cytosines plays a critical role in
inhibiting the expression of cellular genes. In contrast, our
laboratory previously showed that the EBV protein, BZLF1
(Z), which mediates viral reactivation and replication,
preferentially binds to, and activates, the methylated form
of the viral BRLF1 promoter. To date, however, BRLF1 is the
only EBV promoter known to be activated by Z in this
unusual manner. Here, we show that another EBV
promoter (Nap, driving transcription of the BRRF1 gene)
likewise has two methylation-dependent Z binding sites,
and that Z only activates the Nap efficiently in the
methylated form. Molecular modeling studies suggest
why methylation of the Nap enhances Z binding. Since the
BRLF1 and BRRF1 genes encode essential viral transcription
factors that work cooperatively with Z to induce the lytic
form of viral infection, our results indicate that methylation
of the EBV genome enhances Z-mediated disruption of
viral latency.
BZLF1 Binds Methylated ZREs in the Na Promoter
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Immunoblotting
Immunoblotting was performed as described previously [22,42].
Briefly, cells were lysed in SUMO lysis buffer; equivalent amounts
of protein were then separated in sodium dodecyl sulfate-10%
polyacrylamide gel electrophoresis gels (SDS-PAGE) and trans-
ferred to membranes. Membranes blocked in 5% milk then
incubated at room temperature for 1 h with the appropriate
primary antibodies diluted in 5% milk in 16 PBS and 0.1%
Tween 20 (PBS-T). Primary antibody dilutions were as follows:
1:250 anti-BRLF1 (Argene), 1:250 anti-ZEBRA (Santa Cruz, sc-
53904), 1:250 anti-EA-D (Vector), 1:300 anti-Na rabbit antibody
[18] and 1:5,000 anti-b-actin (Sigma). After washing, the
appropriate horseradish peroxidase conjugated secondary anti-
bodies (Pierce) were used at a dilution of 1:7,000 in 5% milk in 16
PBS-T for 1 h at room temperature and washed. Bound
antibodies were visualized by use of enhanced chemiluminescent
reagent (Pierce) according to the manufacturer’s instructions.
In vitro DNA methylation
In vitro DNA methylation of the luciferase constructs was
accomplished with CpG methylase (SssI methyltransferase; New
England Biolabs), by following the procedure recommended by
the manufacturer. Completion of DNA methylation was confirmed
by digestion with the restriction enzyme HpaII (New England
Biolabs), which cleaves its recognition sequence only if the DNA is
not methylated at the cytosine residue within the CpG motif.
Luciferase assays
Luciferase assays were performed 48 h after transfection by
using extracts prepared by freeze-thawing the cell pellet in reporter
lysis buffer according to the instructions of the manufacturer
(Promega). Luciferase activity was assayed using the luciferase
reporter assay system (Promega) as suggested by the manufacturer.
Chromatin immunoprecipitation (ChIP) assay
293 Z-KO cells (36107 cells per condition) were transfected
with a control vector or vector encoding Z and harvested after
20 h for ChIP assays using a modified Upstate ChIP protocol
(Millipore, Billerica, MA). Chromatin was sonicated to ,400 bp.
Antibodies used were control goat polyclonal immunoglobulin G
(IgG)(Santa Cruz, sc-2028) and goat anti-ZEBRA (vE-20) (Santa
Cruz, sc-17503). Input (total) DNA was obtained from samples not
incubated with antibody. ChIP DNA was analyzed using the
following primers: Nap (59-CCC TGT TGT TTC GGA GAA
TGG CCC-39 and 59-GGA AGA CTT TCT GAG GCT AAC
TCC TG-39); oriLyt (59-GCG TCT GGA CGA CGC TGG
CGA-39 and 59-CTC CAG GTA CCA CCC ACC TGG TG-39)
and BALF5 (59-GCG TAG AAG TAG GCC TGC T-39 and 59-
CGG AAG CCC TCT GGA CTT C).
Probes for electrophoretic mobility shift assay (EMSA)
A series of probes spanning the BRLF1 promoter sequences
(from 21 to 2270) or the BRRF1 (Nap) promoter sequences from
2280 to 2470, 2108 to 2301, and +77 to 2128 (relative to the
BRRF1 mRNA start site) were created by PCR amplification and
were 32P end-labeled with T4 Polynucleotide Kinase (New
England Biolabs) in accordance with the manufacturer’s instruc-
tions. In addition, a series of oligonucleotide probes were
synthesized as shown below (with positions of the oligonucleotides
in the EBV genome relative to the BRRF1 start site shown in
parentheses). ZRE sequences are underlined. The oligonucleotides
were synthesized without methylated cytosines at the CpG motif(s)
within potential ZRE sites (MWG Biotech). The double-stranded
oligonucleotides were either left unmethylated or methylated in
vitro using M. SssI CpG methylase (New England Biolabs), then
purified by phenol-chloroform extraction and ethanol precipita-
tion. Oligonucleotides containing Rp ZRE2, Rp ZRE3 and a
consensus AP1 site from the EBV BMRF1 promoter were also
synthesized. Additionally, a series of oligonucleotides with or
without methylated cytosines at the CpG motif(s) in potential Nap
ZREs were synthetically synthesized (Sigma). Double-stranded
oligonucleotide probes were end labeled with 32P using T4
Polynucleotide Kinase. Oligonucleotide sequences are as follows
(with the cytosine of the CpG motif is shown in boldface type):
Nap ZRE-1 (241 to 258) 59-CAT TCT CGC CCG TGG GCC-
39 and 59-GGC CCA CGG GCG AGA ATG-39; Nap ZRE-2
(270 to 283) 59-GTT GAG CGT GGC CA-39 and 59-TGG
CCA CGC TCA AC-39, BMRF1 AP1 59-GAT GAC CTT TGA
GTC AGG TGG CTA-39 and 59-TAG CCA CCT GAC TCA
AGG GTC ATC-39, Rp ZRE3 59-TAT AGC ATC GCG AAT
TTT-39 and 59-AAA ATT CGC GAT GCT ATA-39, Rp ZRE2
59-TAA AAT CGC TCA TAA GCT TA-39 and 59-TAA GCT
TAT GAG CGA TTT TA-39.
EMSAs
In vitro translated wild-type and mutant Z proteins were
generated using TNT T7 Quick Coupled Transcription/Trans-
lation System (Promega) in accordance with the manufacturer’s
instructions. Z binding reactions were carried out in a buffer
consisting of 100 mM KCl, 20 mM HEPES (pH 7.3), 10%
glycerol, 0.2 mM EDTA and 4 mM dithiothreitol (DTT) with
2 mg of poly(dI/dC)/poly(dI/dC) (Pharmacia). 2 mL of in vitro
translated protein were added to each reaction and incubated at
4uC for 10 min before adding labeled probe (20,000 c.p.m.). The
reactions were incubated for 30 min at 4uC before being loaded
onto a 4% polyacrylamide gel and separated in 0.56Tris-borate-
EDTA buffer at 35 mA at room temperature. Image quantifica-
tions were performed using ImageQuant software.
Determining the methylation status of Nap in the viral
genome of EBV-infected cell lines
Total genomic DNA was isolated from cultured EBV-positive
cells using the DNeasy tissue kit (QIAGEN). Bisulfite modification
of genomic DNA was performed using the EpiTect bisulfite kit
(QIAGEN) in accordance with the manufacturer’s instructions.
The modified DNA was amplified by PCR using the EBV BRRF1
promoter primers: 59-GTGTTTATGGTGGTAGGAATTAT-
TAT-39 and 59-CAACTAAACTCTCTAATCTCTAACTAC-
39. Thermal cycler conditions for the PCR were as follows: 1
cycle at 95uC for 10 m followed by 35 cycles of 95uC for 30 s,
52uC for 40 s, 70uC for 40 s, and a final extension of 72uC for
7 m. PCR products were agarose gel purified with a QIAGEN gel
extraction kit and then cloned into the pT7Blue Perfectly Blunt
Cloning Kit (Novagen). For each cell line, 5 to 10 clones were
sequenced to determine the methylation status of the Na
promoter.
Molecular modeling
Structures of Z bound to four different ZREs were modeled
based on the crystal structure of Z (S186A, C189S) bound to the
AP1 site (PDB code: 2c9l) using the Sybyl program. Residues 186
and 189 of Z were changed back to wild type sequence; and the
AP1 sequence was replaced by the sequence of each ZRE followed
by addition of a methyl group to the C5 position of each CpG.
Modeling was finished by several rounds of manual model
building and energy minimization.
BZLF1 Binds Methylated ZREs in the Na Promoter
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Accession numbers
EBV genome, type 1 NC_007605; Z (BZLF1) Swiss-Prot
P03206.
Results
Z preferentially binds to the methylated form of the Na
promoter (Nap)
Regulation of the Nap by viral and cellular factors has not been
well studied. Although the Nap was previously reported to be
activated by Z, but not R, in reporter gene assays, specific ZRE
sites required for Z activation of the Nap were not defined [18].
Furthermore, although the Nap has a number of potential CpG-
containing ZRE motifs, the effect of methylation on Z binding to
the Nap has not previously been examined. To determine if Z
binds to the Nap in the context of the intact viral genome, latently
EBV infected 293 cells were transfected with a Z expression vector
or a control vector, and ChIP assays were performed 20 hours
later to detect Z binding. As shown in Fig. 1A, the ChIP assays
confirmed that Z binds to the Nap in vivo.
To locate potential ZRE sites in the Nap, we performed EMSAs
using in vitro translated Z and a series of unmethylated or
methylated probes spanning the Nap sequences between 2470
and +77. The methylated form of a probe containing BRLF1
promoter (Rp) sequences (from 21 to 2270) served as a positive
control for Z binding. The only Nap probe that had detectable Z
binding contained Nap promoter sequences from 2128 and +77
(relative to the BRRF1 transcriptional start site)(Fig. 1B). Further-
more, Z bound to the methylated form of this Nap probe more
efficiently than to the unmethylated form. These results suggested
that Z may preferentially activate the methylated form of Nap.
Methylation of the Nap inhibits its constitutive activity
Although promoter DNA methylation generally inhibits the
ability of cellular transcription factors to activate gene expression,
we previously showed that methylation of the EBV Rp enhances
its ability to be activated by Z in co-transfection reporter gene
assays [22,34]. To examine how Nap methylation affects its ability
to be activated by cellular and viral factors, we inserted the Nap
sequence upstream of the luciferase gene to create the Nap-LUC
construct. In the absence of promoter DNA methylation, Nap had
strong constitutive activity in two different EBV-negative epithelial
cell lines (HaCaT and HONE-1) as well as an EBV-negative B cell
lymphoma line (DG75)(Fig. 2A). In comparison to the Nap, the
constitutive activity of an Rp-driven luciferase construct (Rp-LUC)
was much weaker in all three cell lines. These results suggest that
the unmethylated form of the Nap has strong constitutive activity
in a variety of EBV-negative cell lines.
To examine the effect of Nap methylation on its activation by
cellular factors, we methylated or mock-methylated the Nap-LUC
vector, or the promoterless luciferase vector (pGL3-basic), with
M.SssI prior to transfection. Digestion of the reporter constructs by
HpaII was used to verify their methylation status (data not shown).
The constitutive activity of the methylated Nap-LUC vector was
much lower than that of the unmethylated construct in both HeLa
cells (Fig. 2B) and DG75 cells (Fig. 2C). The low level activity of
the promoterless control vector (presumably driven by cryptic
binding sites for cellular transcription factors) was likewise
decreased by methylation. These results indicate that methylation
of the Nap inhibits the ability of cellular transcription factors to
activate this promoter.
Methylation of the Nap is required for efficient Z
activation
To examine how methylation of the Nap affects its ability to be
activated by Z, we transfected HeLa cells with methylated or
mock-methylated forms of the Nap-LUC vector in the presence or
absence of a Z expression vector. We also examined the effect of
methylation on Z activation of Rp-LUC, BHLF1p-LUC (a
luciferase vector driven by the early viral BHLF1 promoter, in
which the known ZREs cannot be methylated), or the promoter-
less control luciferase vector (pGL3-basic). Z clearly activated the
methylated form of Nap-LUC much more efficiently than the
unmethylated form (140-fold activation versus 13-fold) in HeLa
cells (Fig. 3A). Similar results were obtained in the EBV-negative B
cell line, DG75 (Fig. 3B). As previously described [34],
methylation of the Rp also enhanced its ability to be activated
by Z (Fig. 3A). In contrast to its effects on the Rp and Nap,
methylation of the BHLF1p (which contains CpG-free ZREs)
strongly inhibited its ability to be activated by Z (Fig. 3A). Z also
induced detectable activation of the promoterless luciferase vector
in HeLa and DG75 cells (perhaps reflecting the presence of a
previously described cryptic AP1 motif in the luciferase vector)
[43], and this activation was inhibited by methylation (Fig. 3A and
3B). These results indicate that both the Nap and Rp are
preferentially activated by Z in the methylated form, consistent
with the presence of methylation-dependent ZREs in their
promoters.
Figure 1. Z binds to the Na promoter, and binding is enhanced
by Nap methylation. (A) Latently infected EBV+ 293 Z-KO cells were
transfected with a BZLF1 expression vector (+) or an empty vector
control (2). Chromatin immunoprecipitation assay was performed
20 hours after transfection using anti-Z and control goat IgG antibodies
as indicated to examine Z binding to the Na promoter (Nap), ZREs
within the EBV oriLyt (positive control) and EBV sequences in the 39 end
of the EBV BALF5 gene (negative control). (B) The ability of in vitro
translated Z to bind to 32P end-labeled probes (in either the
methylated, or unmethylated forms) containing the BRRF1 promoter
(Nap) sequences from 2280 to 2470, 2108 to 2301, and +77 to 2128
(relative to the BRRF1 mRNA start site) was examined by EMSA. A probe
containing the BRLF1 promoter (Rp) sequences from 21 to 2270 (in
the methylated form) served as a positive control.
doi:10.1371/journal.ppat.1000356.g001
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The Nap has two CpG-containing ZREs that are only
bound by Z in the methylated form
To map the precise location(s) of the ZREs in the Nap, we
synthesized oligonucleotide probes spanning each of the various
CpG motifs located within the Nap sequences between 2128 and
+77, as well as potential predicted ZREs without CpG motifs, and
examined the ability of Z to bind to these probes in the methylated
or unmethylated forms. We identified two CpG-containing ZREs,
located between 253 to 247 (‘‘Nap ZRE1’’) and 281 to 275
(‘‘Nap ZRE2’’). Surprisingly, neither of these Nap ZRE sites is
Figure 2. Methylation inhibits constitutive activity of the Nap.
(A) Reporter constructs containing no promoter (pGL3-basic), the R
promoter (Rp-LUC) or the Na promoter (Nap-LUC) driving luciferase
were transfected into HONE-1, HaCaT or DG75 cells. The luciferase
activity produced by each vector is shown (relative to the luciferase
activity of the promoterless vector, set as 1). HeLa (B) and DG75 (C)
cells were transfected with reporter constructs containing no promoter
Figure 3. Methylation of the Nap promotes Z activation. HeLa
(A) and DG75 (B) cells were transfected with a promoterless luciferase
vector, or luciferase vectors driven by the Na, R, or BHLF1 lytic EBV
promoters, in the presence or absence of a co-transfected Z expression
vector. Luciferase vectors were either mock-methylated or methylated
in vitro using M.Sss1 prior to transfection as indicted and the amount of
luciferase activity determined 48 hours after transfection. The fold-
increase in promoter activity in the presence of co-transfected Z (versus
a vector control) is shown (obtained from duplicate transfections).
doi:10.1371/journal.ppat.1000356.g003
(none) or the Na promoter (Nap) driving luciferase. Luciferase vectors
were either mock-methylated or methylated in vitro using M.Sss1 prior
to transfection as indicted. The decrease in luciferase activity derived
from the methylated versus unmethylated promoter constructs is
indicated (activity of the unmethylated constructs is set at 100%).
doi:10.1371/journal.ppat.1000356.g002
BZLF1 Binds Methylated ZREs in the Na Promoter
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detectably bound by Z in the unmethylated form (Fig. 4A). In
contrast, the CpG-containing ZRE sites in the Rp bind to Z in
both the methylated and unmethylated forms, albeit more much
efficiently in the methylated form (Fig. 4A). Thus, Z binding to the
CpG-containing ZREs in the Nap is even more methylation-
dependent than Z binding to the CpG-containing ZREs in the Rp.
We did not identify any strong Z binding sites using a series of
oligonucleotide probes containing potential unmethylated ZREs in
the Nap (data not shown).
The Nap ZRE1 site (TCGCCCG) contains two CpG motifs. To
determine if Z binding to the Nap ZRE1 motif requires methylation
of one, or both, cytosines, we synthesized probes that contained one
methylated cytosine at either CpG motif, or had both CpGs
methylated. As shown in Fig. 4B, Z only binds to the Nap ZRE1 site
when both cytosines are methylated. Thus, methylated cytosines at
positions 22 and +2 are both essential for Z binding to the
methylated Nap ZRE1 site.
The Nap ZRE2 site (ACGCTCA) is similar to the Rp ZRE2 site
(TCGCTCA). Although the Rp ZRE2 site and the Nap ZRE2 site
differ only at position 23 (which is a thymine in the Rp site versus
an adenine in the Nap site), Z binds to both the unmethylated and
methylated forms of the Rp ZRE2 site, whereas it only binds to the
methylated form of the Nap (ZRE2 site) (Fig. 4A). Thus, this one
basepair alteration in the ZRE is sufficient to convert the ZRE to
completely methylation-dependent Z binding. In contrast to the
Nap ZRE2 site, the Nap ZRE1 site (TCGCCCG) is quite different
from all previously reported ZREs and is unique in containing
methylated cytosines located at both positions 22 and +2.
Nap ZRE1 and ZRE2 are both required for Z activation of
methylated Nap
To determine if both the Nap ZRE1 and ZRE2 sites are
important for Z activation of the methylated Nap-LUC vector, we
constructed site-directed mutants of the Nap-LUC that altered the
ZRE1 and/or ZRE2 sites as shown in Fig. 5A. Z activation of
methylated Nap-LUC was strongly reduced by mutation of either
ZRE1 or ZRE2 (Fig. 5B). These results indicate that the ability of
Z to activate the methylated form of Nap in vivo to a high level
requires the presence of two different CpG-containing ZRE sites.
Efficient Z activation of other early lytic viral promoters, such as
BMRF1, has likewise been shown to require at least two ZREs
[44,45].
Serine residue 186, but not cysteine residue 189, is
required for Z binding to methylated Nap ZREs
A Z mutant in which the Ser186 residue in the basic DNA
binding domain is converted to an alanine (the equivalent residue
in c-jun and c-fos) binds poorly to the methylated forms of Rp
ZRE2 and Rp ZRE3, but binds at least as well as wild-type Z to
the consensus AP1 site [22]. More recently, converting Z residue
Cys189 to a serine residue was reported to inhibit Z binding to
methylated Rp ZRE3, but not AP1 [46]. To determine whether Z
residue 186 or 189 regulates Z binding to methylated ZREs in
Nap, we compared the ability of in vitro-translated wild-type Z,
Z(S186A) and Z(C189S) to bind to labeled oligonucleotide probes
containing the Nap ZRE1 and ZRE2 sites, the consensus AP1 site
from the BMRF1 early viral promoter, or the Rp ZRE2 and ZRE3
sites. The probes were synthesized such that they contained
methylated cytosines at the CpG motifs. The Z(S186A) mutant
was highly impaired in comparison to wild-type Z for binding to
the methylated forms of the Nap ZRE1 and ZRE2 sites, as well as
the Rp ZRE2 and ZRE3 sites, but, as expected, was able to bind
to the consensus AP1 site at least as well as wild-type Z (Fig. 6A).
The Z(C189S) mutant was slightly impaired for binding to the
methylated forms of the Rp ZRE2 and Nap ZRE2 sites, but highly
impaired for binding to the methylated forms of Nap ZRE1 and
Rp ZRE3 (Fig. 6A). These results indicate that residue Ser186 is
absolutely required for Z binding to three of the four known
methylation-dependent ZREs (Rp ZRE3, Nap ZRE1 and Nap
ZRE2), and greatly enhances Z binding to the other methylated
ZRE (Rp ZRE2). In contrast, the requirement for Cys189 varies
between the different methylation-dependent ZREs.
Serine residue 186 is required for activation of the
methylated Nap
To determine whether Z residue Ser186 is required for
activation of the methylated Nap in vivo, we compared the ability
of wild-type Z, versus the Z(S186A) mutant, to activate the
methylated Nap-LUC construct. The methylated forms of the
Nap-LUC or Rp-LUC vectors were co-transfected into HeLa cells
with a control vector or vectors expressing either wild-type Z or
Z(S186A). Consistent with its inability to bind to methylated Nap
ZRE1 and ZRE2 in the EMSAs, Z(S186A) was impaired in the
Figure 4. Z preferentially binds to the methylated forms of ZRE
sites in the Nap. (A) The ability of in vitro translated Z to bind to
labeled oligonucleotide probes containing potential ZRE sites in the
Nap was examined by EMSA using methylated or mock-methylated
probes as indicated. Nap sequences (with probable ZRE sites
underlined) were (Nap ZRE1, 258 to 241): 59-CAT TCT CGC CCG TGG
GCC-39 and (Nap ZRE2, 283 to 270): 59-GTT GAG CGT GGC CA-39.
Binding to the unmethylated and methylated forms of two CpG-
containing ZREs in the BRLF1 promoter (Rp) was also examined. The
relative efficiency of Z binding to each probe is indicated; the amount
of Z binding to the methylated Rp ZRE3 probe is arbitrarily set as 100%.
ND: none detected. (B) The ability of in vitro translated Z to bind to the
labeled oligonucleotide Nap ZRE1 probe (258 to 241) containing no
methylated cytosine, one methylated cytosine, or two methylated
cytosines was compared. The methylated cytosine(s) present in each
probe are indicated by a bold C in the sequence.
doi:10.1371/journal.ppat.1000356.g004
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Figure 5. Nap ZRE1 and ZRE2 are required for Z activation of the methylated Nap. (A) site-directed mutations of the two ZREs in Nap-LUC
were constructed as indicated. Specific base pairs altered are underlined. (B) HeLa cells were transfected with the methylated Nap-LUC constructs
(wildtype versus mutant) in combination with either the empty vector (vector) or the Z expression vector (Z). The amount of luciferase activity
determined 48 hours after transfection is shown (obtained from duplicate transfections).
doi:10.1371/journal.ppat.1000356.g005
Figure 6. Serine residue 186 is required for Z binding to the ZREs in the Nap. (A) EMSA was performed using either methylated or mock-
methylated oligonucleotide probes containing the Nap ZRE1, Nap ZRE2, Rp ZRE2, Rp ZRE3 and BMRF1p AP1 sites and in vitro translated wild-type Z
(WTZ), ZS186A or ZC189S. The relative efficiency of WTZ, versus mutant Z, binding to each probe is indicated; the amount of WTZ binding to each
probe is arbitrarily set as 100%. ND: none detected. (B) The amount of Z protein used in the EMSAs in (a) was quantitated by immunoblot for WT and
mutant proteins.
doi:10.1371/journal.ppat.1000356.g006
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ability to activate the methylated form of Nap (Fig. 7). As
previously reported [22,34], Z(S186A) was also defective in
activating the methylated form of Rp. These results indicate that
Z Ser186 is important for activating the methylated forms of both
Rp and Nap in vivo. Thus, the previously reported finding that the
Z(S186A) mutant is unable to disrupt viral latency in the context of
the intact viral genome [36,37] may reflect not only its inability to
activate the Rp, but also its inability to activate the Nap.
The Nap is highly methylated in latently infected cells
Although the Rp was previously shown by our laboratory to be
highly methylated in a variety of different latently infected EBV-
positive cell lines [22], the methylation status of the Nap has not
been previously reported. To examine this, we isolated DNA from
a) 293 cells infected with a BZLF1-deleted virus, b) HONE-1/
EBV cells (an NPC line super-infected with EBV), c) SNU-719
cells (a gastric carcinoma line which has remained EBV-positive in
culture) or d) Raji cells (an EBV-positive Burkitt lymphoma line),
and then treated the DNA with sodium bisulfite, converting
unmethylated, but not methylated, cytosine residues into thymine
residues. Following bisulfite treatment, the Nap sequence was
PCR-amplified and cloned into the pT7Blue vector (Novagen). A
number of different clones derived from each cell line were
sequenced to determine the methylation status of the Nap. As
shown in Table 1, the ZREs in the Nap were both highly
methylated in each cell line. These results suggest that the ability of
Z to bind to the methylated forms of the two ZREs in Nap is likely
essential for its ability to activate Na transcription in latently
infected cells.
Wild-type Z but not Z(S186A) activates Na and R
expression in latently infected 293 cells
To determine if Z binding to the methylated form of the Nap is
required for Z activation of Na expression in the context of the
intact viral genome, we compared the ability of wild-type Z, the
Z(S186A) mutant, or the Z(C189S) mutant to activate Na
expression in the presence or absence of an R expression vector
in 293 cells stably infected with a BZLF1-deleted mutant EBV. In
the context of the intact latent viral genome, both Z and R are
required to induce expression of most early lytic gene promoters
[8]. As previously reported [36,37], the Z(S186A) mutant by itself
was not able to induce expression of the R protein, or the early
viral protein EA-D (BMRF1) (Fig. 8). This defect was observed
even when the Z(186A) mutant was expressed at extremely high
levels (data not shown). However, in combination with an R
expression vector, Z(S186A) activated EA-D, consistent with the
known ability of this mutant to bind to the BMRF1 promoter
ZREs. Furthermore, in comparison to wild-type Z, the Z(S186A)
mutant was also impaired for the ability to activate expression of
Na, and this defect persisted even when the R protein was supplied
in trans. The Z(C189S) mutant was similar to wild-type Z in its
ability to activate R, EA-D and Na expression, consistent with its
ability to bind (at least weakly) to one or more ZREs in each
promoter. These results confirm that the ability of Z to bind to the
methylated form of the Nap is required for efficient Z activation of
Na expression in the context of the intact viral genome in latently
infected cells.
Modeling Z interactions with methylated and
unmethylated ZREs
The sequences of the consensus AP1 site (from the BMRF1p), a
ZRE which is bound by Z in the unmethylated form (from the
Figure 7. Serine residue 186 is required for Z activation of the
methylated Nap in vivo. HeLa cells were transfected with methylated
luciferase vectors driven by the Na or R promoters, in the presence or
absence of a co-transfected wild-type Z (WTZ), or the Z(S186A) mutant
altered in the DNA binding domain at residue 186. The amount of
luciferase activity produced by each condition (obtained from duplicate
transfections) is indicated.
doi:10.1371/journal.ppat.1000356.g007
Table 1. Methylation of the Nap ZREs in the EBV genome.
Cell Line Description ZRE2 ZRE1 22 ZRE1 +2
293-ZKO superinfected 293 5/5 5/5 4/5
HONE-1/EBV superinfected NPC 7/8 7/8 7/8
SNU-719 EBV+ gastric 8/8 8/8 7/8
Raji EBV+ BL 8/8 8/8 8/8
The cytosine methylation status of the CpG motifs within the ZRE1 and ZRE2
sites in the Nap in different latently infected EBV+ cell lines is shown. The
number of clones found to contain a methylated CpG in each Nap ZRE, versus
the number of clones sequenced in each cell line (following bisulfate
treatment), is indicated.
doi:10.1371/journal.ppat.1000356.t001
Figure 8. Wild-type Z, but not Z(S186A), activates Na and R
transcription. Wild-type Z (WTZ), Z(S186A), Z(C189S) or empty vector
(vector) were transfected in to 293 Z-KO cells in the presence or
absence of an R expression vector and assayed by western blot for
expression of Z, R, Na, EA-D or b-actin.
doi:10.1371/journal.ppat.1000356.g008
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Rp), and the four known methylation-sensitive ZREs (from the Rp
and Nap) are compared in Fig. 9. Interestingly, the ZREs which
are bound by Z in the methylated form all have a CpG motif in
the left half-site at the same position (leading to methylated
cytosines at 22 and +1’).
To explore why methylation of some ZRE sites is required for Z
binding, we used the Sybyl program to model the interaction of Z
with the newly discovered methylated Nap ZREs versus the AP1
site. Consistent with previous observations modeling the binding of
Z to methylated ZREs in the Rp [35,46], our model of Z binding
to the methylated Nap ZRE2 left-half site (Fig. 10A, upper panel)
indicates that the cytosine methyl group at +1’ occupies the same
position as the thymine methyl group (+1’) in the AP1 site
(Fig. 10A, lower panel). Interestingly, this cytosine is present in the
same location within the left half-sites of all four methylation-
sensitive ZREs (Fig. 9).
We also observed that methylation of cytosines in the Nap
ZRE2 site helps to define the sidechain conformation of the Z
Ser186 and Asn182 residues, and stabilize a hydrogen bonding
network. Upon methylation, the two cytosine methyl groups (+1’
and 22) limit the sidechain movement of Ser186, stabilizing its
hydrogen bonds to the amine groups of both cytosines (+1’ and
22) and to the carbonyl group of Asn182. This helps define the
sidechain of Asn182 to a different conformation which allows it to
form hydrogen bonds with several DNA bases, including the
guanine at +2’ which is present in the left half-site of all four
methylation-sensitive ZREs (Fig. 9). In addition, this conformation
of Asn182 stabilizes a hydrogen bond with the adenine at 23 in
Nap ZRE2 (Fig. 10A). The adenine at 23, which is occupied by a
thymine in the other methylated and unmethylated ZREs, as well
as AP1 (Fig. 9), is unique to the Nap ZRE2 site. Thus, the
hydrogen bonds in this network appear to be most abundant with
the Z/Nap ZRE2 complex, helping to explain why the Nap ZRE2
interaction with Z absolutely relies on methylation. In addition,
this architecture explains why mutation of Ser186 to alanine,
which would attenuate this hydrogen bonding network, greatly
abrogates Z binding to methylated Nap ZRE2.
A model of Z bound to the right half-site of the methylated Nap
ZRE1 site, which has a unique CpG not present in the other
methylated ZREs, is shown in Fig. 10B. Similar to position +1’, the
methylated cytosine at position 23’ of Nap ZRE1 mimics the
thymine present at 23’ in AP1 and all other methylated ZREs
(Fig. 10B). Our model demonstrates that methylation of the
cytosines in the right half-site of Nap ZRE1 helps to stabilize the
sidechain of Asn182’ to a different conformation, allowing it to
form hydrogen bonds with the altered nucleotides at 23’ and +3.
Methylation of the cytosine at 23’ also defines the sidechain
conformation of Ser186’ and Arg190’, and stabilizes the hydrogen
bonds between Ser186’ and Arg190’, and between Arg190’ and
two phosphate groups of DNA backbone.
Interestingly, the Rp ZRE3 right half-site has a unique thymine
at 22’ (Fig. 9), which leads to van der Waals contacts of this
thymine to Cys189 (Fig. 10C, yellow contour). This interaction is
absent in other ZREs and AP1, which have a common guanine at
this position (Fig. 10C, purple contour). Mutation of Cys189 to a
serine residue (Fig. 10C, red contour) is predicted to greatly reduce
the van der Waals contact to the 22’ thymine of Rp ZRE3.
Collectively, this explains why Cys189 is most important for Z
binding to Rp ZRE3.
Discussion
The EBV Z protein, which mediates the switch from latent to
lytic viral infection, is to date the only transcription factor shown to
preferentially bind to, and activate, the methylated form of a target
promoter. However, only one EBV promoter (Rp) has previously
been shown to be preferentially bound, and activated, by Z in the
methylated form. Indeed, all other previously identified Z binding
sites in early lytic promoters do not even contain CpG motifs. Thus,
whether methylated CpG-containing ZRE sites are specifically
important for Z activation of the Rp, but not other viral promoters,
has remained unclear. In this report, we identify two CpG-
containing ZREs in the EBV early lytic Nap, and show that these
ZREs are only bound by Z in the methylated state. Furthermore, we
demonstrate that the Nap can only be activated by Z efficiently in
vivo when the promoter is methylated. In addition, we show that
both Nap ZREs are generally methylated in the EBV genome of
latently infected cells. Our molecular modeling studies of Z bound
to these new Nap ZREs help to explain why methylation of these
sites is required for Z binding. Together, these results indicate that
methylation of the EBV genome not only enhances Z activation of
R transcription, but is required for Z activation of Na transcription.
This apparently unique feature of Z likely helps the virus to
efficiently activate lytic viral gene transcription when the viral
genome is highly methylated. Conversely, the inability of Z to
induce expression of the viral transcription factors, R and Na, from
the incoming (unmethylated) viral genome may help the virus to
establish latency.
Our laboratory previously showed that Z preferentially binds to
and activates the methylated EBV BRLF1 gene promoter, Rp,
through two CpG-containing ZREs. Z does not bind to all
methylated CpG motifs, but rather binds to methylated CpGs
embedded within ZRE-like motifs [22,34]. In the case of the Rp,
we found that Z binds to both the unmethylated, as well as
Figure 9. Comparison of ZRE sites. Sequences of the consensus
AP1 site, the three Rp ZRE sites and the two Nap ZREs are shown.
Methylated cytosines are indicated with an asterisk.
doi:10.1371/journal.ppat.1000356.g009
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methylated, forms of the Rp ZRE2 and Rp ZRE3 sites (Fig. 4A)
(although binding to the methylated form is much more efficient,
particularly in the case of the Rp ZRE3). The Rp also has one
ZRE (Rp ZRE1) which does not contain a CpG and therefore
cannot be methylated. Of note, while Z activates the methylated
form of the Rp more efficiently than the unmethylated form, it
clearly also activates the unmethylated form of Rp (Fig. 3A). The
ability of Z to activate unmethylated Rp is likely mediated by
binding to the unmethylated Rp ZRE1 and ZRE2 sites.
In the case of the Nap, both of the ZREs identified contain CpG
motifs, and require methylation for Z binding. Furthermore, Z
binding to the highly atypical Nap ZRE1 site (TCGCCCG),
which contains two CpG motifs, requires methylation of both
CpGs. Consistent with this methylation-dependent binding of Z to
the Nap in vitro, we found that methylation of the Nap is required
for efficient Z activation of a Nap driven luciferase reporter
construct in vivo. In fact, Z activation of the Nap may be even more
dependent upon promoter DNA methylation than Z activation of
Rp. Site-directed mutation of either ZRE in the Nap greatly
abrogated Z activation of the methylated Nap-luciferase construct,
indicating that the presence of both ZREs is important for Z
activation. While Nap methylation is required for Z activation, we
found that it has the opposite effect on the ability of cellular
transcription factors to activate the Nap. Thus, although the Nap
has high constitutive activity in the unmethylated form, it is
completely inactive in the methylated form unless Z is present.
Although a previous report suggested that bacterially produced
His-tagged Z protein can bind to the unmethylated form of Nap
[18], we found only weak Z binding to the unmethylated form of
the Nap using in vitro translated Z as a source of protein in EMSAs.
Therefore, a post-translational modification of Z that does not
occur in bacterial cells, or an interaction with another cellular
protein(s), may be required to observe methylation-dependent Z
binding to the Nap ZREs. Z was also reported to activate the
unmethylated form of Nap in a reporter gene assay [18]. We
speculate that this previous result may reflect the ability of Z to
activate certain reporter gene constructs through a non-DNA
binding mechanism when expressed at very high levels and/or the
presence of cryptic AP1 sites in some reporter gene vectors [47].
To date, Z activation of lytic viral genes in the context of the intact
viral genome requires direct Z binding to the viral promoters.
Cellular factors could potentially stabilize weak Z binding to the
unmethylated form of Nap in some cell types.
We and others have previously shown that a Z(S186A) mutant
binds very poorly to the methylated forms of Rp ZRE2 and Rp
ZRE3, even though this alteration does not affect Z binding to the
consensus (and unmethylated) AP1 motif [22]. Furthermore, the
Z(S186A) mutant cannot disrupt viral latency when transfected
into latently infected cells, and this phenotype is at least partially
reversed when the R protein is supplied in trans, expressed under
the control of a constitutively active promoter [36,37]. In this
paper, we have shown that the Z mutant, Z(S186A), is severely
impaired for binding to each of the four known methylated ZRE
sites in EBV. Consistent with its methylation-dependent binding
defect, the Z(S186A) mutant is unable to activate the methylated
Nap reporter construct in vivo, or to induce Na expression from the
methylated viral genome in latently infected cells even in the
Figure 10. Modeling of Z binding to methylated ZRE sites
versus AP1. (A) The predicted structure and hydrogen interactions
between WT Z bound to Nap ZRE2 (upper panel, stereoview) is
compared to Z(S186A) bound to the AP1 site (lower panel, stereoview).
Z is shown as a green ribbon; hydrogen interactions are indicated by
dotted black lines and the two DNA strands are shown as orange and
cyan tubes. The left half-sites of Nap ZRE2 and AP1 are shown in cyan
basepair stick as indicated. (B) Stereoview illustration of Z binding to
the right half-site of methylated Nap ZRE1 is shown. A purple ball-and-
stick model highlights the key difference of the Z/AP1 structure (at
position 23’ thymine and +3 adenine) compared to the Z/Nap ZRE1
structure, as well as the different sidechain conformations of Asn182’.
(C) Z Cys189 forms van der Waals contacts with the 22’ thymine
unique to Rp ZRE3. Van der Waals contacts between the 22’ thymine
position unique to the Rp ZRE3 DNA molecule and Cys189 are
highlighted (yellow contour). This interaction is greatly reduced with a
guanine present at the 22’ position (purple contour). Additionally,
mutation of Cys189 to a serine residue greatly reduces the van der
Waals interaction (red contour) with the 22’ Rp ZRE3 thymine.
doi:10.1371/journal.ppat.1000356.g010
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presence of a co-transfected R expression vector. The finding that
the Z(S186A) mutant is defective not only for BRLF1 (R) gene
activation, but also for BRRF1 (Na) gene activation, suggests that
loss of both R and Na protein expression may contribute to its
phenotype.
Although the crystal structure of Z bound to the consensus AP1
site has been published [35], the crystal structure of Z bound to a
methylated ZRE site has not yet been reported. Karlsson et al.
recently suggested that Z residue Ser186 stabilizes Z binding to the
left half-sites of methylated Rp ZRE2 and Rp ZRE3 by directly
interacting with the methyl group of the cytosine located at
position +1’, and thereby stabilizing a hydrogen bonding network
involving Ser186, Asn182 and the guanine located at +2’ [46].
Our models agree with this notion except that more hydrogen
bonds were identified in this network, particularly in Z bound to
Nap ZRE2 (Fig. 10A, upper panel). The difference in the
hydrogen bond network of Z/Nap ZRE2 appears to be
contributed by its unique adenine at the 23 position. Its hydrogen
bond to Asn182 requires that the carbonyl and the amine groups
of the Asn182 sidechain are in the opposite direction (Fig. 10A,
upper panel) compared to AP1 (Fig. 10A, lower panel). We
hypothesize that stabilization of this conformation in Nap ZRE2
relies more on this methylated CpG motif than in Rp ZRE2,
which differs from Nap ZRE2 only at the 23 position. This is
consistent with our observation that unmethylated Nap ZRE2 fails
to bind Z while unmethylated Rp ZRE2 can still bind. In all of our
models, Ser186 appears to play a central role in bridging the
hydrogen bond networks, consistent with the observation that
Z(S186A) is impaired for binding to all four known methylated
ZREs in EBV. In addition to the left half-site, Ser186’ clearly plays
a role in forming a second hydrogen bond network, interacting
with the unique CpG motif on the right half-site of Nap ZRE1;
this network also relies on methylation of the CpG motif (Fig. 10B).
The sidechain conformation of Asn182’ likewise changes in
context of the altered sequence of the Nap ZRE1 right half-site
for hydrogen bond formation (Fig. 10B). Thus, the ability of Z to
recognize different ZREs partially relies on stabilization of Asn182
conformations for formation of hydrogen bonds that vary
depending on the context of different DNA sequences.
Consistent with previous observations, the common CpG motif
at the left half-site gives rise to a methylated cytosine at the +1’
position in all four methylation-sensitive ZREs that mimics the
structure of thymine in AP1 (Fig. 10A). Interestingly, the unique
CpG motif at the right half-site of Nap ZRE1 also gives rise to a
methylated cytosine at the 23’ position that mimics the structure
of the common 23’ thymine present in most other ZREs, as well
as in AP1 (Fig. 10B). This observation suggests that the ability of
methylated cytosines to mimic thymine in DNA-protein interac-
tions might be a more common phenomenon.
Another factor regulating the binding of Z to DNA is the redox
state of the bZIP domain [48,49]. This regulation is conserved in
many of the bZIP proteins, including c-fos and c-jun. In contrast,
DNA binding of C/EBPa, which contains a serine residue in the
place of the usual cysteine residue, is insensitive to the redox
environment. Z possesses the bZIP protein conserved cysteine at
residue 189, and the DNA-binding function of Z is redox
dependent [49]. Karlsson et al. recently reported that Z(C189S)
is defective in binding to the methylated Rp ZRE3 site (although
this defect was not redox dependent), and based on this finding
proposed that Z Cys189 directly contributes to Z binding to at
least some methylated ZREs [46]. In our experiments, we
confirmed that Z(C189S) is highly impaired for binding to the
methylated form of the Rp ZRE3 site, as well as the Nap ZRE1
site, but much less impaired for binding to the methylated forms of
Nap ZRE2 and Rp ZRE2. These results suggest that Z Cys189, in
contrast to Z Ser186, is required for binding to a limited subset of
methylated ZREs. Consistent with the previous model of Z bound
to Rp ZRE3 [46], our model likewise predicts that van der Waals
contacts occur between the 22’ thymine position unique to the Rp
ZRE3 DNA molecule and Z Cys189 (Fig. 10C). However, the
Z(C189S) mutant is not predicted to have these interactions. Our
finding that Z(C189S) binds to some methylation-dependent ZREs
more efficiently than to the Rp ZRE3 site may reflect the absence
of a thymine at the 22’ position in these other ZREs. As
previously reported [46], we found that the Z(C189S) mutant
induces lytic infection in latently infected 293 cells almost as well as
wild-type Z, perhaps reflecting our previous finding that some Rp
ZREs are unmethylated in this cell type [22].
The fact that the Rp and Nap are potentially the only EBV
promoters which are preferentially bound, and activated, by Z in
the methylated form suggests that these two promoters may be
activated in tandem. Since our laboratory has previously shown
that Na cooperates with R to activate the Z promoter in the
context of the intact viral genome [19], the ability of the Z protein
to activate both R and Na transcription efficiently from the
methylated form of the viral genome may serve as an essential
positive autoregulatory loop in the initial stage of viral reactivation.
However, since the EMSA assays performed to search for ZREs in
lytic EBV promoters have not generally used methylated DNA
probes, many undiscovered methylation-dependent ZREs may yet
exist in the EBV genome. Whether there are also methylation-
dependent ZREs in the cellular genome remains unknown.
We previously showed that demethylation of the EBV genome
in latently infected 293 cells inhibits the ability of Z to induce lytic
viral gene expression [34], strongly suggesting that viral genome
methylation promotes the ability of Z to activate lytic genes in the
context of the intact viral genome. Based upon the results
presented here, we propose the following model to illustrate how
EBV uses R and Na promoter methylation to enhance both the
latent, and lytic, forms of infection. In cell types (such as
oropharyngeal epithelial cells) where viral infection is normally
completely lytic, and thus the viral genome does not become
methylated, we propose that R and Na, rather than Z, may be the
primary mediators of lytic gene expression, since the ability of R
and Na to induce Z expression does not require viral genome
methylation (and in fact may be inhibited by methylation). During
infection of cells (such as B cells) that normally undergo the latent
form of infection, the inability of Z to activate R and Na
transcription efficiently from the incoming unmethylated viral
genome helps the virus to establish latency. Following establish-
ment of viral latency, the viral genome eventually becomes highly
methylated (potentially reflecting the ability of the virally encoded
latent LMP1 protein to activate expression of the cellular
methyltransferase 1 protein [50,51]). Methylation of the Na and
R promoters inhibits their ability to be activated by cellular
transcription factors, further promoting viral latency as long as the
Z protein is not available. However, following reactivation of Z
expression by stimuli such as plasma cell differentiation,
methylation of the Na and R promoters enhances Z binding,
perhaps ensuring that a limiting amount of Z preferentially binds
to ZREs in the R and Na promoters. Alternatively, the
conformation of full-length Z bound to methylated ZREs may
be subtlety different from its conformation bound to unmethylated
ZREs. If so, Z bound to methylated ZREs may interact more
strongly with co-activator proteins such as CBP, and thus activate
promoters with methylated ZREs more efficiently [52]. In
combination, expression of the Z, R and Na proteins is then
sufficient to initiate the entire lytic cascade of viral gene expression.
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